Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MOREWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MOREUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don’t find the answers you’re looking for, contact us for additional assistance.
EXPLORE MORECD20 (Cluster of Differentiation 20), also called B lymphocyte antigen CD20, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells, in human it is encoded by MS4A1 gene. CD20 plays a role in the development and differentiation of B-cells into plasma cells.its function is to enable optimal B-cell immune response, specifically against T-independent antigens.CD20 is expressed on all stages of B cell development except the first and last. It has been found that associated with B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. Therefore CD20 have been considered as a therapeutic target of monoclonal antibodies such as rituximab, obinutuzumab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias.
Associated Disease
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | Inquiry & Datasheet |
| CAR-NK-1-M327-2 | Anti-CD20 scFv h(CD28) CARNK, pCDCAR1 | Human | rituximab | Chimeric | scFv-CD28 | Lentiviral | NK cell | |
| CAR-NK-1-M327-G | Anti-CD20 scFv h(FcεRIγ) CARNK, pCDCAR1 | Human | rituximab | Chimeric | scFv-FcεRIγ | Lentiviral | NK cell | |
| CAR-NK-1-M327-Z | Anti-CD20 scFv h(CD3ζ) CARNK, pCDCAR1 | Human | rituximab | Chimeric | scFv-CD3ζ | Lentiviral | NK cell | |
| CAR-NK-2-M327-2Z | Anti-CD20 scFv h(CD28-CD3ζ) CARNK, pCDCAR1 | Human | rituximab | Chimeric | scFv-CD28-CD3ζ | Lentiviral | NK cell | |
| CAR-NK-2-M327-4G | Anti-CD20 scFv h(CD4-FcεRIγ) CARNK, pCDCAR1 | Human | rituximab | Chimeric | scFv-CD4-FcεRIγ | Lentiviral | NK cell | |
| CAR-NK-2-M327-4Z | Anti-CD20 scFv h(CD4-CD3ζ) CARNK, pCDCAR1 | Human | rituximab | Chimeric | scFv-CD4-CD3ζ | Lentiviral | NK cell | |
| CAR-NK-2-M327-8Z | Anti-CD20 scFv h(CD8-CD3ζ) CARNK, pCDCAR1 | Human | rituximab | Chimeric | scFv-CD8-CD3ζ | Lentiviral | NK cell | |
| CAR-NK-2-M327-BG | Anti-CD20 scFv h(CD28-FcεRIγ) CARNK, pCDCAR1 | Human | rituximab | Chimeric | scFv-CD28-FcεRIγ | Lentiviral | NK cell | |
| CAR-NK-2-M327-BZ | Anti-CD20 scFv h(41BB-CD3ζ) CARNK, pCDCAR1 | Human | rituximab | Chimeric | scFv-41BB-CD3ζ | Lentiviral | NK cell | |
| CAR-NK-2-M327-CZ | Anti-CD20 scFv h(b2c-CD3ζ) CARNK, pCDCAR1 | Human | rituximab | Chimeric | scFv-b2c-CD3ζ | Lentiviral | NK cell | |
| CAR-NK-3-M327-2BZ | Anti-CD20 scFv h(CD28-41BB-CD3ζ) CARNK, pCDCAR1 | Human | rituximab | Chimeric | scFv-CD28-41BB-CD3ζ | Lentiviral | NK cell | |
| CAR-NK-3-M327-2XZ | Anti-CD20 scFv h(CD28-OX40-CD3ζ) CARNK, pCDCAR1 | Human | rituximab | Chimeric | scFv-CD28-OX40-CD3ζ | Lentiviral | NK cell | |
| CAR-T-1-M302-2 | Anti-CD20 scFv h(CD28) CART, pCDCAR1 | Human | 1F5 | Mouse | scFv-CD28 | Lentiviral | T cell | |
| CAR-T-1-M302-G | Anti-CD20 scFv h(FcεRIγ) CART, pCDCAR1 | Human | 1F5 | Mouse | scFv-FcεRIγ | Lentiviral | T cell | |
| CAR-T-1-M302-Z | Anti-CD20 scFv h(CD3ζ) CART, pCDCAR1 | Human | 1F5 | Mouse | scFv-CD3ζ | Lentiviral | T cell | |
| CAR-T-2-M302-2G | Anti-CD20 scFv h(CD28-FcεRIγ) CART, pCDCAR1 | Human | 1F5 | Mouse | scFv-CD28-FcεRIγ | Lentiviral | T cell | |
| CAR-T-2-M302-2Z | Anti-CD20 scFv h(CD28-CD3ζ) CART, pCDCAR1 | Human | 1F5 | Mouse | scFv-CD28-CD3ζ | Lentiviral | T cell | |
| CAR-T-2-M302-4G | Anti-CD20 scFv h(CD4-FcεRIγ) CART, pCDCAR1 | Human | 1F5 | Mouse | scFv-CD4-FcεRIγ | Lentiviral | T cell | |
| CAR-T-2-M302-4Z | Anti-CD20 scFv h(CD4-CD3ζ) CART, pCDCAR1 | Human | 1F5 | Mouse | scFv-CD4-CD3ζ | Lentiviral | T cell | |
| CAR-LY078 | Anti-CD20 (2H7) h(41BB-CD3ζ) CAR, pCDCAR1 | Human, Monkey | 2H7 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | |
| CAR-LY1718 | Anti-CD20(2H7) h(CD28-CD3ζ) CAR, pCDCAR1 | Human, Monkey | 2H7 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | |
| CAR-YF011 | Anti-CD20 (Ofatumumab) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | Ofatumumab | Human | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | |
| CAR-YF012 | Anti-CD20 (Ofatumumab) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | Ofatumumab | Human | scFv-CD28-CD3ζ | Lentiviral vector | T cell | |
| CAR-YF013 | Anti-CD20 (Rituximab) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | Rituximab | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | |
| CAR-YF014 | Anti-CD20 (Rituximab) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | Rituximab | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | |
| CAR-YF015 | Anti-CD20 (Obinutuzumab) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | Obinutuzumab | Human | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | |
| CAR-YF016 | Anti-CD20 (Obinutuzumab) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | Obinutuzumab | Human | scFv-CD28-CD3ζ | Lentiviral vector | T cell | |
| CAR-YF399 | Anti-CD20 (2H7) h(-CD3ζ) CAR, pCDCAR1 | Human | 2H7 | Mouse | scFv-CD3ζ | Lentiviral vector | T Cell | |
| CAR-YF400 | Anti-CD20 (2H7) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 2H7 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | |
| CAR-YF402 | Anti-CD20 (2H7) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 | Human | 2H7 | Mouse | scFv-CD28-41BB-CD3ζ | Lentiviral vector | T Cell | |
| CAR-YF403 | Anti-CD20 (Leu-16) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | Leu-16 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | |
| CAR-YF404 | Anti-CD20 (Leu-16) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | Leu-16 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T Cell | |
| CAR-YF419 | Anti-CD20 (Ofatumumab) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 | Human | Ofatumumab | Human | scFv-CD28-41BB-CD3ζ | Lentiviral vector | T Cell | |
| CAR-ZP8836 | Anti-CD20 (BA0185) h(CD28-CD3ζ) CAR, pcDCAR1 | EBV | BA0185 | Rabbit | scFv-CD28-CD3ζ | Lentiviral vector | T cell | |
| CAR-ZP8837 | Anti-CD20 (BA0185) h(4-1BB-CD3ζ) CAR, pcDCAR1 | EBV | BA0185 | Rabbit | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | |
| CAR-ZP8465 | A uniCAR [Anti-GCN4 CAR], with a Fab-based CAR Adaptor [Anti-CD20 (Ofatumumab)], a Switchable CAR System | Mature B cell neoplasms | Lentiviral vector | |||||
| CAR-ZP8478 | A uniCAR [Anti-FITC CAR], with a mAb-based CAR Adaptor [Anti-CD20 (Rituximab)], a Switchable CAR System | Mature B cell neoplasms | Lentiviral vector | |||||
| CAR-ZP8485 | A uniCAR [Anti-biotin CAR], with a mAb-based CAR Adaptor [Anti-CD20 (Cetuximab)], a Switchable CAR System | Mature B cell neoplasms | Lentiviral vector | |||||
| CAR-ZP8486 | A uniCAR [Anti-CD16 (FCGR3A) 158(V/V)(FCGR3A)-CD3TM/ CD3ζ], with a mAb-based CAR Adaptor [Anti-CD20 (Rituximab)], a Switchable CAR System | Mature B cell neoplasms | Lentiviral vector | |||||
| CAR-ZP8491 | A uniCAR [Anti-CD16 CAR], with a mAb-based CAR Adaptor [Anti-CD20 (Obinutuzumab)], a Switchable CAR System | Mature B cell neoplasms | Lentiviral vector | |||||
| CAR-YF706 | Anti-CD20 (2B8) h(CD3ζ) CAR, pCDCAR1 | Human | 2B8 | Mouse | scFv-CD3ζ | Lentiviral vector | T Cell | |
| CAR-YF765 | Anti-CD20 (2B8) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 2B8 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | |
| CAR-YF820 | Anti-CD20 (2B8) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 2B8 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T Cell | |
| CAR-YF877 | Anti-CD20 (2B8) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 | Human | 2B8 | Mouse | scFv-CD28-41BB-CD3ζ | Lentiviral vector | T Cell | |
| CAR-YF935 | Anti-CD20 (2B8) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | 2B8 | Mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T Cell | |
| CAR-ZP8489 | A uniCAR [anti-CD16 (FCGR3A) V158 variant-CD8ɑ/41BB/ CD3ζ], with a mAb-based CAR Adaptor [Anti-CD20 (Rituximab)], a Switchable CAR System | Mature B cell neoplasms | Lentiviral vector | |||||
| CAR-ZP8492 | A uniCAR [anti-CD16 (FCGR3A) 48H and V158 variant-CD 28TM/CD28ICD/CD3ζ], with a mAb-based CAR Adaptor [Anti-CD20 (Rituximab)], a Switchable CAR System | Mature B cell neoplasms | Lentiviral vector | |||||
| CAR-ZP8497 | A uniCAR [anti-CD16A (V158) CD8TM/CD28-CD3ζ], with a mAb-based CAR Adaptor [Anti-CD20 (Rituximab)], a Switchable CAR System | Mature B cell neoplasms | Lentiviral vector | |||||
| CAR-ZP8498 | A uniCAR [anti-CD16A-41BB/CD3ζ], with a mAb-based CAR Adaptor [Anti-CD20 (Rituximab)], a Switchable CAR System | Mature B cell neoplasms | Lentiviral vector |
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.
LEARN MORE
Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.
LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.
LEARN MORE
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE
